Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulranumab
- Development stage
- Phase 3
- Lead developer
- Janssen Research & Development
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Fulranumab is a fully human recombinant immunoglobulin G2 (IgG2) monoclonal antibody that specifically binds to and neutralizes nerve growth factor (NGF), thereby inhibiting its biological activity. NGF is a neurotrophin involved in the modulation of pain signaling and is upregulated in various pain states. By blocking NGF, fulranumab was developed as a potential analgesic for chronic pain conditions such as osteoarthritis and diabetic peripheral neuropathic pain. The drug was originally developed by Amgen and later licensed to Johnson & Johnson (Janssen). Clinical trials demonstrated efficacy in reducing moderate to severe pain; however, all phase III trials were discontinued by Johnson & Johnson in 2016 due to strategic portfolio prioritization rather than safety concerns[1][4][5][6].
- Other names
- fulranumab
02
Targets
NGF (Nerve growth factor)
Beyond the preview
Go deeper on fulranumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulranumab.